T2 values of each sample or well were calculated from your captured MRI by fitting the decay curve on a pixel-by-pixel basis using the non-linear mono-exponential algorithm of Mi = M0 exp(?TEi/T2). Tumor-bearing mice were scanned using a 3T MRI scanner with a customised rodent coil to collect pre- and post-contrast enhanced MRI data. epidermal growth factor receptor (EGFR) signaling pathway plays an important role in the regulation of cell proliferation, survival, and differentiation.[1,2] Upregulation of EGFR is found in many cancer types, which provides an opportunity for designing receptor-targeted approaches for cancer detection and treatment.[3,4] The difference in the level of EGFR expression between normal cells and tumor cells, coupled with the phenomenon of the cellular internalization of EGFRCantibody complexes, suggests that EGFR is usually a potential marker for in vivo receptor-targeted molecular imaging with excellent tumor-to-background contrast, and that EGFR is a good mediator for the targeted drug delivery.[5,6] Previous studies have examined the feasibility of conjugating imaging contrast brokers or nanoparticles with EGF, the natural ligand to EGFR, and the monoclonal antibody Lerociclib (G1T38) to EGFR in vitro.[7-10] However, the use of a growth stimulating ligand to target EGFR has limitations when used in developing an application for cancer patients. Although several anti-EGFR monoclonal antibodies have been used for malignancy treatment in patients, they have a relatively large size, which limits the number of ligands that can be linked to the surface of a nanoparticle and impedes intratumoral distribution due to interstitial tumor pressure. For example, an immunoglobulin G (IgG) antibody has an common size of 14.5 8.5 4 nm3 and a molecular weight of 160 kDa.[11,12] As an alternative for generating EGFR-targeted nanoparticles, a single-chain anti-EGFR antibody (ScFvEGFR) provides a much smaller targeting ligand. A single-chain Fv (scFv) fragment consists of antibody heavy- and light-chain variable domains connected with a flexible peptide linker. The producing antibody fragment (25 to 28 kDa) is usually smaller than 20% Lerociclib (G1T38) of an intact antibody but maintains a high binding affinity and specificity.[6,13] Recently, several types of nanoparticles including quantum dots (QDs), magnetic iron oxide (IO), gold, and polymer-based nanoparticles have been developed for malignancy applications.[14-18] The concept of designing and synthesizing tumor-targeted or multi-functional nanoparticles for cancer imaging and therapy has been demonstrated and the results show that nanotechnology may provide new means for in vivo tumor-targeted imaging and drug delivery.[17,19,20] However, the challenges for the development of tumor-targeted nanoparticles for in vivo applications are also recognized. For instance, it is important to take into account that this nanoparticles should not only be stable enough to generate strong imaging signals, but should also have a altered surface with reactive functional groups for efficient conjugation of tumor targeting ligands and therapeutic brokers. At present, fluorescence emitting quantum dots (QDs), a class of light-emitting nanoparticles, have been utilized for biomarker-targeted in vivo tumor imaging.[14,15] Another type of nanoparticle, magnetic iron Lerociclib (G1T38) oxide (IO) nanoparticles, is particularly attractive and feasible for molecular imaging in the clinical setting because of prior applications of magnetic resonance imaging (MRI), their biocompatibility and surface chemistry allowing for the introduction of functional biomolecules.[16,21,22] Non-targeted magnetic IO nanoparticles have been used in imaging liver tumors and lymph node metastasis in human prostate malignancy patients.[23,24] Several studies have used dextran or poly(ethylene glycol) (PEG)-coated IO nanoparticles to develop targeted imaging contrast brokers by attaching targeting ligands, such as antibodies against Her-2/Neu or transferrin, folate acid, or tumor targeting short peptides.[16,17,22,25-27] Results of these studies demonstrated the feasibility of using targeted nanoparticle probes for MRI of subcutaneously implanted tumors in animal models. However, several issues remain to be addressed to increase the sensitivity and specificity of the receptor-targeted tumor imaging brokers for future use in malignancy patients. Typical hurdles encountered for in vivo applications include heterogeneous levels of expression of the targeted receptor in human tumor cells, numerous physiological barriers preventing the nanoparticle from reaching the targeted cells, and lack of information around the intratumoral distribution and imaging capability of targeted nanoparticles within tumor sites that are relevant to the locations of most human main and metastatic tumors. In this study, we developed EGFR-targeted nanoparticles that specifically bind TIMP1 to and are internalized by EGFR-expressing tumor cells, which are present in a high percentage of the epithelial tumor types. To determine the specificity of ScFvEGFR to.